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Objectives: Randall initially described calciﬁ  ed subepithelial papillary plaques, which he 
hypothesized as nidi for urinary calculi. The discovery of calcifying nanoparticles (CNP), also 
referred to as nanobacteria, in calciﬁ  ed soft tissues has raised another hypothesis about their 
possible involvement in urinary stone formation. This research is the ﬁ  rst attempt to investigate 
the potential association of these two hypotheses.
Methods: We collected renal papilla and blood samples from 17 human patients who had 
undergone laparoscopic nephrectomy. Immunohistochemical staining (IHS) was applied using 
monoclonal antibody (mAb) against CNP. Homogenized papillary tissues and serum samples 
were cultured for CNP. Scanning electron microscopy (SEM) and energy dispersive X-ray 
spectroscopy (EDS) were performed on papillary samples. Serum samples were tested for CNP 
antigen and antibody with enzyme-linked immunosorbent assay (ELISA).
Results: Randall’s plaques (RP) were visible on gross inspection in 11 out of 17 samples. IHS 
was positive for CNP antigen in 8 of the visually positive samples, but in only 1 of the remaining 
samples. SEM revealed spherical apatite-formations in 14 samples conﬁ  rmed by EDS analysis. 
In cultures, all serum samples and 13 tissue homogenates grew CNP. In ELISA, 14 samples 
were positive for CNP-antigen and 11 samples were positive for CNP-antibody.
Conclusion: There was evidence of a link between detection of CNP and presence of RP. 
Although causality was not demonstrated, these results suggest that further studies with nega-
tive control samples should be made to explore the etiology of RP formation, thus leading to a 
better understanding of the pathogenesis of stone formation.
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Introduction
Seventy years ago, Randall examined the papillae of cadaveric renal units and dem-
onstrated that interstitial crystal plaques in the papillary tip were common in stone 
formers (Randall 1937). These crystals were composed not of calcium oxalate (CaOx), 
the most common solid phase found in patients with nephrolithiasis, but of calcium 
phosphate (CaP). He believed that the CaP crystals serve as a nucleation surface for 
CaOx (Randall 1940). In vitro, CaP phases efﬁ  ciently nucleate CaOx crystallization 
(Mandel et al 1996), so that one can easily conjecture that common CaOx stones begin 
on plaques. Recently, Matlaga and colleagues (2007) analyzed RP and conﬁ  rmed that 
they are formed of spherical CaP deposits with a multilaminated internal morphology 
(Figures 1A, B). According to the Merck Manual (2006), all pathological calciﬁ  ca-
tions contain snowball-like CaP spheres 200 nm in size. However, the identity of those 
spherical formations has remained elusive.
Structures similar to the snowballs were discovered over a decade ago in blood 
and blood products (Kajander et al 1998). These structures, CNP, were detected in 
numerous pathological calciﬁ  cations, such as in kidney stones (Ciftcioglu et al 1999;
Khular et al 2004), in atherosclerotic plaques (Miller et al 2004; Puskas et al 2005), International Journal of Nanomedicine 2008:3(1) 106
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in psammoma bodies of cancer (Hudelist et al 2004), in 
prostatic stones (Shoskes et al 2005), and in gallbladder 
(Wen et al 2005). CNP are calciﬁ  ed (Kajander et al 1998), 
self-propagating (Ciftcioglu et al 2006) entities, morpho-
logically very similar in mineral composition to spherical 
bodies observed in RP (Figure 1A-D). Due to lack of their 
genomic evidence, CNP are controversial agents as prions 
were, and critics have proposed hypotheses explaining them 
as precipitates of proteins or crystals (Cisar et al 2000). 
Although CNP cause speciﬁ  c infection (Ciftcioglu et al 
2007), and are detected in pathological calciﬁ  cation, general 
debate over their existence continues. Methods to detect CNP 
include immuno-detection techniques using anti-CNP mAbs, 
culture-techniques and electron microscopy (Miller-Hjelle 
et al 2003). With these methodologies, important features 
of CNP and their triggering effect on nephrolithiasis have 
been suggested: A) CNP consist of tiny, “cell-like” spheres 
(80–200 nm). They precipitate apatite from media forming 
apatite-protein complexes on their exterior membrane. 
This protein-associated mineralization (Vali et al 2001) can 
reach a diameter of one to several micrometers (Kumar et al 
2006; Benzerara et al 2006). B) 14% of healthy adults in 
Scandinavia have anti-CNP antibodies (Holmberg 2001). In 
comparison, 75% of patients with kidney diseases have CNP 
antigen in blood (Hjelle et al 2000). C) CNP form apatite 
units/shells in vitro, morphologically and chemically similar 
to those in the core of kidney stones, (Figure 2) (Ciftcioglu 
et al 1999). D) CNP are renotropic (Åkerman et al 1997). 
E) CNP cause renal stones when injected into rats (Garcia 
Guerpo et al 2000). F) CNP have been detected in kidney 
stones (Ciftcioglu et al 1999). G) In vitro, destruction of the 









Figure 1 Morphological similarities of published TEM images of spherical, apatite-containing formations in renal papillae (A and B) and CNP (C and D). Magniﬁ  cations: A, 20,000X; 
B, 30,000X; C and D, bars 200 nm. Reprinted from A: Coe FL, Evan A, Worcester E. 2005. Kidney stone disease. J Clin Invest, 115:2598–2608, with permission from American 
Urological Association. B: Matlaga BR, Coe FL, Evan AP, et al 2007. The role of Randall’s plaques in the pathogenesis of calcium stones. J Urol, 177:31–38, with permission from 
American Urological Association. C: Kajander EO, Ciftcioglu N. 1998. Nanobacteria: an alternative mechanism for pathogenic intra- and extracellular calciﬁ  cation and stone 
formation. Proc Natl Acad Sci USA, 95:8274–8279, with permission from National Academy of Sciences USA. D: Kajander EO, Ciftcioglu N, Aho K, et al 2003. Characteristics of 
nanobacteria and their possible role in stone formation. Urol Res, 31:47–54, with kind permission from Springer Science and Business Media.International Journal of Nanomedicine 2008:3(1) 107
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numerous 50 to 100 nm diameter membranous cells (Kumar 
et al 2006) similar to those observed in Randall plaques by 
other research groups (Matlaga et al 2007). H) TEM study 
of renal plaques shows 1–5 µm apatite spheres, similar to the 
structure of CNP (Figure 1) (Kajander et al 1998; Matlaga 
et al 2007).
In this study, our aim was to investigate the associa-
tion between the presence of CaP spheres found in RP and 
detection of CNP. Such an association would be a basis for 
a formal hypothesis that can be discussed, and used to drive 
further studies in larger patient groups.
Materials and methods
Subjects
Renal papillae were dissected from 17 patients who had 
undergone laparoscopic nephrectomy due to neoplasia (renal 
cell carcinoma, n = 9; transitional cell carcinoma, n = 4; Other 
malignancies; n = 4). Presence or absence of RP was evaluated 
on gross inspection of immediately extracted and bivalved 
kidneys. Intact papillae were harvested well away from the 
tumor, and were prepared for the analyses with IHS, SEM, 
EDS and CNP culture. Blood was drawn from fasting patients 
before and after surgery. The serum was used for CNP culture 
and ELISA to detect CNP antigen and antibody. Bladder urine 
samples of patients were collected for routine bacterial culture. 
The study was approved by the UCSF Committee on Human 
Research and committee patient conﬁ  dentiality and informed 
consent protocols were followed.
Tissue preparation for analysis
Papillary specimens of 17 patients for IHS and SEM 
experiments were immersed in 4% paraformaldehyde and 
refrigerated overnight. IHS samples were parafﬁ  n embedded 
and prepared for IHS as described earlier (Scheffer et al 
2002). SEM samples were dehydrated and gold-coated 
as described previously (Matlaga et al 2007). The tissue 
samples for CNP cultures were placed into 2 ml of sterile 
phosphate buffered saline (PBS), pH 7.4, homogenized for 
30-seconds, four times, with 30-second cooling intervals on 
ice using conventional glass tissue-grinders. Homogenized 
tissue was centrifuged at 2500 g for 15-minutes. The super-
natant was separated and sterile-ﬁ  ltered through 0.22 µm 
pore size, nonprotein binding ﬁ  lters (Millipore) into sterile 
nonadhesive tubes and stored at −70 °C until processed for 
culture as described below.
IHS analysis of papillary samples
Parafﬁ  n-embedded papillary samples were cut into 5 µm sec-
tions, deparafﬁ  nized and rehydrated (Scheffer et al 2002). Each 
tissue section was demineralized in 250 mM sodium citrate for 
24-hours at +4 °C, to retrieve apatite crystal-covered epitopes 
prior to IHS. After washing in water, endogenous peroxidase 
was blocked with 1% H2O2 in methanol for 30-minutes. Slides 
were rinsed in PBS before staining with a catalyzed-signal-
ampliﬁ  cation IHS (Dako, Carpinteria, CA, USA). Anti-CNP 
mAb, 8D10 (Nanobac Oy, Kuopio, Finland), was used as 
primary antibody and counterstained with hematoxylin. Nega-
tive control sections went through the same staining process, 
except that the primary mAb step was omitted.
CNP cultures from serum and tissue 
samples
The samples were cultured in Dulbecco’s Modiﬁ  ed Eagle’s 
Medium (DMEM, Gibco Lab Inc., Grand Island, NY) under 
B A
Figure 2 SEM images showing the similarity of apatite spheres in various sizes in the core of an oxalate kidney stone (A) and apatite formations in the CNP culture (B). 
Bars = A; 1 µm, B; 10 µm.International Journal of Nanomedicine 2008:3(1) 108
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Table 1 ELISA result ratings
Units/ml  −  +  ++  +++  ++++
Nanocapture  3.5 3.5–10.9  11.0–49.9  50.0–149.90  150
NanoSero  0.1 0.1–0.39  0.4–0.49 0.5–0.69  0.7
cell culture conditions (37 °C, 5%–10% CO2, 90%–95% 
humidity) for 4 weeks. Patient sera were cultured at 10% ﬁ  nal 
concentration, and tissue homogenates were cultured both 
with and without fetal bovine serum (FBS) supplementation 
which previously tested negative for CNP (Atlanta Biologi-
cals, GA) as described earlier (Miller-Hjelle et al 2003). The 
homogenized tissue pellets were incubated with 30 mM 
EDTA for 1-hour at room temperature for decalciﬁ  cation, 
diluted 1:10 in DMEM, and cultured as described above. To 
eliminate potential conventional-bacterial contamination, 
each sample was ﬁ  ltered through 0.22 µm pore-sized ﬁ  lters 
before culturing. Cultures were checked for gross bacterial 
contamination by microscopy and macroscopic observation 
of turbidity and medium color change from the third day 
of incubation. Controls containing only culture media were 
incubated in parallel with the test cultures to determine 
whether spontaneous precipitation can occur. Every week, 
cultures were inspected by phase contrast microscopy (Nikon 
Eclipse TE 2000-U) for CNP propagation. Positive identiﬁ  ca-
tion of CNP involved typical slow propagation and optical 
properties, negative signal with Hoechst 33258 dye, and posi-
tive signal with indirect immunoﬂ  uorescence staining (IIFS) 
(Ciftcioglu et al 2006). Serum and tissue homogenate cultures 
for CNP were rated (+) = growth in four weeks, (++) = in 
three weeks, (+++) = in two weeks, and (++++) = in one 
week, and (−) = no growth in four weeks of incubation. All 
culture samples were harvested by 14000 g centrifugation 
for 30-min at 4 °C after 30-days of incubation. The pellets 
were analyzed for IIFS using CNP surface-antigen-speciﬁ  c 
mAb 8D10, followed by Alexa Fluor 488 goat-anti-mouse 
IgG antibody (Miller-Hjelle et al 2003). In addition, Hoechst 
stain was used to detect conventional bacterial contamination. 
As a positive control for Hoechst, E. coli (nonpathogenic 
strain HB101) was used. Fluorescence photographs were 
taken using an Olympus BX60F5 microscope coupled to a 
Nikon digital camera DXM 1200F.
SEM and EDS microanalysis
Papillary samples 2–4 mm in block size were analyzed 
both for morphology and chemical composition using 
JEOL 6340 Field Emission SEM with attached IXRF 
EDS analyzer (Kajander et al 1998). Each sample was 
divided into 4 equal mapping areas and scanned for small, 
100–500 nm spherical apatite forms. Cultured CNP and one 
oxalate kidney stone sample (provided by Louis C. Herring 
Laboratory, Orlando, FL) were prepared for SEM analysis 
using the same preparation technique for tissue samples. 
SEM results were rated as (−) = no CNP observed; otherwise 
as the number of mapped areas in which CNP were seen 
(+ to ++++).
Biochemical assays
The commercially available ELISA kits for detecting anti-
CNP IgG and CNP-antigen; Nano-Sero IgG ELISA, and 
Nanocapture ELISA (Nanobac Oy, Finland), respectively, 
were used. All measurements were run in duplicates. The 
detection antibody in Nanocapture recognizes CaP-binding 
protein-antigen on CNP in a special CaP complex confor-
mation (ELISA kit inserts). There was not enough serum of 
subject #17 for ELISA tests. ELISA results were rated as 
shown in Table 1.
Statistical analysis
Descriptive results of the various analytic techniques are 
displayed in terms of ratings in Table 2. Association between 
SEM ﬁ  ndings and CNP growth ratings in tissue cultures was 
quantiﬁ  ed in terms of contingency table analysis (Fisher 
Exact Test) with ratings collapsed to either 0 [rating = (−)] 
or 1 [rating = (+) – (++++)]. A similar analysis was made 




Eleven male and 6 female patients were enrolled in our study, 
with a mean age of 66 ± 10 and 78 ± 11 years, respectively. 
Visually, RP were observed on the papillae of 11 patients, with 
no sexual preponderance. No correlation was found between 
the observation of RP and the patients’ tumor types (Table 3). 
Urine cultures for conventional bacteria were negative in 12 
patients, showed mild growth of genital ﬂ  ora in 3 patients and 
were positive for enterococcus species in 2 patients.
IHS
The results of papillae analyzed using IHS is summarized in 
Table 2. Nine out of 17 tissue samples stained positive for CNP 
antigen. Positive staining results, as a brown-colored precipitate 
at the antigen site, are shown in Figures 3A, B, and F. Negative 
controls that were stained with the same technique by omitting International Journal of Nanomedicine 2008:3(1) 109
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the mAb did not show any nonspeciﬁ  c signal (Figure 3E). Eight 
papillary samples were IHS negative. (Figures 3C, D).
CNP cultures of serum samples 
and tissue homogenates
All serum samples and 13 of 17 papillary tissue homog-
enates and pellets contained CNP at different growth rates 
(Table 2). Three serum samples were already positive within 
3-days of culture. All propagation-positive samples stained 
positive with IIFS using anti-CNP mAb (Figure 4A), but 
stained negative with the Hoechst (Figure 4B), indicating 
no bacterial contamination in cultures. The positive control 
for Hoechst dye, E. coli, was stained blue (Figure 4D), but 
no nonspeciﬁ  c-signal was detected with 8D10 (Figure 4C). 
None of the samples analyzed with IIFS showed autoﬂ  uo-
rescence prior to staining. SEM of cultured CNP showed 
typical morphology of CNP (Figure 5A), as described earlier 
(Ciftcioglu et al 2006). Control cultures revealed no CNP 
growth, mineralization, or protein precipitation.
SEM Analysis
Fourteen of 17 tissue samples contained CNP-like spheres 
in various sizes (Figures 5B-D and 6B). Tissues with visible 
macroscopic plaques had more apatite spheres compared to 
the samples with nonvisible plaques in SEM (Figure 7). The 
tissue cells with those apatite particles looked more deformed 
with ﬁ  brous formations (Figures 5C, D, and 7F) whereas the 
negative tissue cells appeared more intact (Figures 6A and 
7G). The spheres produced an EDS pattern (Figure 6C) iden-
tical to the CNP EDS patterns as observed in earlier studies 
(Kajander et al 1998; Ciftcioglu et al 1999).
In SEM analysis, oxalate kidney stone had spherical 
units in the core, similar to cultured CNP from renal plaques 
(Figure 2) with identical EDS patterns.
Table 2 Observation of Randall’s plaques on gross inspection, and the detection of CNP by various methods
Sample no  Tissue analysis         Blood analysis
  Randall’s   IHC  SEM  EDS  Tissue    Serum culture   ELISA  Ag  ELISA  Ab
  plaques      homogenate  for  CNP
        culture  for  CNP
1  −  −  −  −  −  +++  +  −
2  +  +  +++  +  −  +++  +  +
3  +  +  +++  +  ++  ++  +++  −
4  +  −  +++  +  +  +  +++  +
5  +  +  +  +  ++  +++  ++  −
6  +  +  +++  +  ++  ++++  −  −
7  −  −  +++  +  ++  +++  +  −
8  +  +  ++++  +  +  ++++  ++++  +
9  −  −  ++++  +  +  ++++  ++++  +
10  −  +  +++  +  ++  ++  ++  +
11  −  −  ++  +  +  +  −  +
12  +  +  −  −  −  +  ++++  +
13  −  −  +++  +  −  +  ++  +
14  +  +  +  +  +  +  ++  +
15  +  +  −  −  +  +  ++++  +++
16  +  −  ++  +  +  +  ++  +
17  +  −  +  +  +++  +++ ND  ND
Positive 11  9  14  14  13  17  14  11
Abbreviations: CNP, calcifying nanoparticles; IHC, immunohistochemistry; SEM, scanning electron microscopy; EDS, energy dispersive X-ray spectroscopy; ND, not done.
Notes: The serum and tissue homogenate cultures for CNP have a rating of ++++: growth in one week, +++: growth in two weeks, ++: growth in three weeks, +: growth in 
four weeks, −: no growth in four weeks of incubation. SEM is rated as 0 if no CNP is observed, 1 if CNP are seen in one of the four mapped areas, 2 if CNP are seen two of 
the four mapped area, 3 if CNP are seen three of the four mapped area, and 4 if CNP are seen in every scanned area at 1500X magniﬁ  cation. ELISA results are rated according 
to the ELISA kit manufacturer’s “1 unit” deﬁ  nition.
Table 3 Association between the observation of Randall’s plaques 
and the patients’ tumor types
Diagnosis RP  + RP  −  p-value (chi-square test
      of diagnosis versus RP)
RCC 4  5  0.18
TCC 3  1  0.92
Other* 4 0 0.28
Abbreviations: RCC, renal cell carcinoma; TCC, transitional cell carcinoma.
Notes: *Including oncocytoma and medullary ﬁ  broma.International Journal of Nanomedicine 2008:3(1) 110
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ELISA
Out of 16 tested serum samples, 14 were positive for CNP-
antigen, and 11 were positive for CNP-antibody. ELISA results 
are summarized at Table 4. Serum samples collected before 
and after surgery had no statistical difference showing that the 
measured biomarkers can be reproducibly measured. The mean 
antigen values before and after surgery were 184.294 ± 273.606 
Units/ml and 180.103 ± 275.644 Units/ml respectively. The 
mean antibody values before and after surgery were 0.169 ± 
0.136 Units/ml and 0.150 ± 0.148 Units/ml respectively.
Association between CNP and SEM 
detection of RP
Two-by-two contingency tables for SEM (detection of 
spherical apatite formations on renal papilla) versus tissue 
culture growth and SEM versus ELISA-Ag concentration 
ratings are shown in Tables 5 and 6, respectively. Note that 
12 of 14 positive SEM samples showed CNP growth, while 
1 of 3 negative samples showed growth (Table 5, p = 0.121, 
Fisher's Exact Test). On the other hand the ELISA-Ag results 
were preponderantly positive regardless of the SEM results 
(Table 6, p = 0.650, Fisher's Exact Test).
Discussion
Plaques, deﬁ  ned as sites of interstitial crystal deposition 
at or near the papillary tip, are found in kidneys of CaOx-
stone formers (100%) and often, but less frequently (43%), 
in people who do not form CaOx stones (Low et al 1997). 
The nucleus of these plaques are composed of CaP (Coe 
et al 2005). Despite extensive studies on RP, the etiology of 
the initial CaP accumulation remains elusive.
Figure 3 Immunohistochemical (IHS) staining of parafﬁ  n-embedded renal tissue by using anti-CNP monoclonal antibody. Brown color shown by black arrows indicates positive 
signal (existence of CNP antigen) in the tissue. The images shown at A (100X) and B (200X) are from renal plaque-positive, IHS-positive tissue. C (100X) and D (400X) are 
from IHS-negative tissue, E and F (200X) are consecutive sections from a positive tissue. E is stained by omitting the monoclonal antibody, showing no positive signal whereas 
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Figure 4 Light microscopic images of double staining results of patient samples cultured under CNP culture conditions. (A) IIFS of cultured patient samples showed positive 
ﬂ  uorescence signal using monoclonal antibody 8D10 when imaged with the green bandpass emission ﬁ  lter, (B) Negative results of Hoechst dye of sample A imaged with the 
blue bandpass emission ﬁ  lter. (C) IIFS of negative bacterial control (nonpathogenic E. coli strain HB101) showed no ﬂ  uorescence signal using CNP-speciﬁ  c monoclonal antibody 
when imaged with green bandpass emission ﬁ  lter. (D) Positive results of Hoechst dye of sample C imaged with the blue bandpass emission ﬁ  lter.
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Figure 6 SEM analysis of renal papilla and EDS analysis. A, Renal cells with no plaques. B, renal cells with plaque formations showing bumpy surface. White arrows show the 
spherical apatite formations on renal cells. C, EDS analysis of the one representative apatite sphere on the cells shown in B.
Figure 7 Images from Randall’s plaques. (A) Tiny calciﬁ  cations at the tip of the renal papilla. (B) Relatively large calciﬁ  ed plaques. (C) A cross section through the renal 
papilla, showing sub-epithelial calciﬁ  cations running deep into the renal medulla (approximately 3 mm). Images of renal papillary tissue with (D) and without (E) visible plaque 
formations. and their SEM images (F) and (G), respectively. Black arrows show streaks of plaques in the tissue, white small arrows show the apatite spheres on the tissue. 
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Table 4 Summary of ELISA results
Units/ml  −  +  ++  +++  ++++
Nanocapture 2/16  2/16  5/16  3/16 4/16
NanoSero 5/16  10/16  1/16  0/16  0/16
The detection of CNP in human urinary stones (Ciftcioglu 
et al 1999; Shiekh et al 2006) inspired the hypothesis that 
CNP might be the initiating agents in the formation of RP 
and subsequently renal stones. CNP resemble the snowballs 
(~0.1–0.5 µm) from pathological calciﬁ  cations described 
by Merck Manual. In addition, they cause rapid in situ 
precipitation of CaP from blood and other body ﬂ  uids under 
conditions not normally conducive to such precipitation 
(Kajander et al 1998). CNP are renotropic, as reported from 
rabbit experiments using injected radiolabelled-CNP and are 
eliminated from the circulation through urinary excretion 
(Åkerman et al 1997). It was also shown that translumbar, 
percutaneous, intrarenal injection of CNP into rats resulted 
in renal stone formation (Garcia-Guerpo et al 2000). Whether 
CNP themselves serve as the nucleus for crystal formation 
by simply lowering the activation barrier or they induce 
calciﬁ  cation by some other mechanism under much lower 
supersaturation conditions is yet to be determined.
In this study, we investigated the presence of CNP in 
the RP of non stone-forming patients. For apparent reasons, 
kidneys could not be obtained from healthy subjects to serve 
as negative controls. Similarly, kidneys from renal stone 
patients are normally not removed, unless complicated by 
severe hydronephrosis or superimposed pyelonephritis. All 
subjects in our study had their kidneys removed due to a 
renal mass.
We observed RP in 65% of the kidneys, and searched for 
CNP in the renal papillae through IHS, SEM, and culture 
techniques. 72% of plaque-positive tissues were positive for 
CNP antigen in IHS whereas 83% of plaque-negative tissues 
were negative, indicating a statistically signiﬁ  cant associa-
tion (p = 0.043). Negative IHS in plaque-positive samples 
could happen if the section plane does not pass through the 
plaque. On the other hand, a plaque-negative sample may 
stain positive if CNP antigen is present in the tissue but 
macroscopically undetectable.
SEM of papillae revealed CNP-like spheres in the 
majority of samples, irrespective of the presence of visible 
RP (Figure 5). As with IHS, CNP morphology may not be 
observed in a plaque-positive tissue if the SEM section plane 
does not include the plaque. Similarly, CNP may be detected 
in a plaque-negative sample in the early stages of plaque 
development. This is in agreement with the hypothesis that 
all large renal stones begin as small calculi and large RP 
begin as minuscule calciﬁ  cations. This may explain some 
of our CNP detection in plaque-negative samples. In EDS 
analysis, only the CNP-like spheres on papillae produced 
calcium and phosphate peaks identical to that of CNP in 
previous reports.
In our earlier TEM analysis of CNP shells, we described 
their morphology as “tree-age-ring-like” formations of crys-
tal and organic matter (Kajander et al 2003), a description 
which is almost identical to observations in RP (Figure 1) 
by others (Coe et al 2005). We also have observed apatite 
spherical-formations in the core of kidney stones independent 
of their overall chemical composition (Figure 2), and cultured 
CNP from those stones (Ciftcioglu et al 1999).
To see if these apatite spheres are actually capable of 
propagating, we cultured the papillary tissue extracts obtained 
from our patients. Thirteen of 17 samples grew CNP within 4 
weeks (Table 2), which were identiﬁ  ed by IIFS of harvested 
culture pellets with the CNP-speciﬁ  c mAb. We cultured 
patient sera obtained before and after surgery, all of which 
turned positive within 4-weeks (Table 3). The differences 
observed in the propagation rate may reﬂ  ect existence of 
CNP in different concentrations. ELISA tests measuring CNP 
antigen (14/16) and antibody (11/16) in sera also strongly 
correlate with culture results.
To a great extent, our studies accord with and conﬁ  rm 
much of Randall’s pioneering work. The plaque is inter-
stitial and composed of apatite. What we add here is that 
many of the apatite formations can propagate in cultures 
and are stainable with CNP-speciﬁ  c mAb. Therefore one 
conclusion could be that RP contain CNP. Where do these 
CNP come from? Stoller and colleagues (1996) suggested 
a vascular origin for RP. We have detected CNP in blood 
(Kajander et al 1998). CNP may form foci or agglomer-
ate in kidneys when excreted in the urine and ultimately 
may develop into RP (Kajander et al 2003). CaP spheres 
200 nm in size have been observed in many pathological 
Table 5 Fisher’s exact analysis of SEM/EDS test results versus 
CNP propagation from the papillary tissue results
SEM/EDS  CNP propagation from     Total
  the tissue homogenate
 0  1 
0 2  1  3
1 2  12  14
Total 4  13  17
Notes: Fisher’s exact = 0.121; 1-sided Fisher's exact = 0.121.International Journal of Nanomedicine 2008:3(1) 114
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calciﬁ  cations (Carson 1998) including atherosclerotic and 
RP. Interestingly, CNP have been detected in similar calci-
ﬁ  cations (Miller et al 2004). CNP could be the elusive CaP 
snowballs found in pathological calciﬁ  cations.
Conclusion
There is a correlation between RP and the presence of CNP. 
If supported by further work, the establishment of CNP as 
the etiology of RP will direct a fundamentally novel treat-
ment approach for urinary stone disease. If so, inhibiting 
the propagation of CNP (Ciftcioglu et al 2002) would make 
urinary stone prevention a conceivable possibility.
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